McKesson (MCK) NDR Confirms a CRO Deal is NOT on the Table - UBS

June 7, 2021 6:31 AM EDT
Get Alerts MCK Hot Sheet
Price: $202.50 -0.06%

Rating Summary:
    18 Buy, 9 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 25 | Down: 37 | New: 115
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

UBS analyst Kevin Caliendo reiterated a Buy rating and $205.00 price target on McKesson (NYSE: MCK) after hosting CFO, Britt Vitalone, for a series of investor meetings on June 4th. The key takeaway from the meetings was that management is adamant that MCK is not looking to add a "third pillar" of growth beyond its current focus on enhancing its oncology and biopharma franchises.

The analyst stated "In speaking about CROs, he stated that while MCK has participated in clinical trials strategy and there are parts of a CRO that could enhance its oncology business, that MCK was not looking to become a full service contract research organization. Instead, MCK will continue to look build out Ontada internally and add technology assets that might enhance that growth."

For an analyst ratings summary and ratings history on McKesson click here. For more ratings news on McKesson click here.

Shares of McKesson closed at $194.94 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Hot Comments

Related Entities

UBS